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Abstract  
Chronic obstructive pulmonary disease (COPD) is a progressive and devastating chronic lung 
condition that has a significant global burden, both medically and financially. Currently there are 
no medications that can alter the course of disease. At best, the drugs in clinical practice provide 
symptomatic relief to suffering patients by alleviating acute exacerbations. Most of current clinical 
research activities are in late severe disease with lesser attention given to early disease 
manifestations. There is as yet, a lack of understanding of the underlying mechanisms of disease 
progression and the molecular switches that are involved in their manifestation. Small airway 
fibrosis and obliteration are known to cause fixed airflow obstruction in COPD, and the 
consequential damage to the lung has an early onset. So far, there is little evidence of the 
mechanisms that underlie this aspect of pathology. However, emerging research confirms that 
airway epithelial reprogramming or epithelial to mesenchymal transition (EMT) is a key 
mechanism that drives fibrotic remodelling changes in smokers and patients with COPD. A recent 
study by Lai et al, further highlights the importance of EMT in smoking-related COPD pathology. 
The authors identify HB-EGF, an EGFR ligand, as a key driver of EMT and a potential new 
therapeutic target for the amelioration of EMT and airway remodelling. There are also wider 
implications in lung cancer prophylaxis, which is another major comorbidity associated with 
COPD. We consider that improved molecular understanding of the intricate pathways associated 
with epithelial cell plasticity in smokers and patients with COPD will have major therapeutic 
implications.  
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
COPD is a lung disease of major international importance and is caused mainly by cigarette 
smoking, although indoor and outdoor pollution are also major contributors in poorer nations 
(1-6). The disease prevalence according to world health organisation (WHO) is estimated to be 
over 250 million persons, and cause up to 3 million deaths annually (2015), which is 5% of 
total worldwide mortality (7). The disease burden is growing rapidly in developing nations 
such as China and India where 90% of the overall deaths occur, partly due to smoking but also 
environmental pollution (8). COPD is characterized primarily as slowly progressive airway 
narrowing with only partial reversibility at most even after smoking cessation. Vulnerable 
smokers increasingly develop small airway fibrosis; airway wall thickening that causes 
narrowing, and subsequent obliteration, accompanied by bronchitis and structural changes that 
are evident throughout the bronchial tree (9). Fifty percent of patients suffer varying degrees 
of emphysematous lung destruction which further adds to airflow obstruction and symptoms 
(10). Nevertheless, airway disease with early small airway destruction is a primary 
phenomenon with subsequent parenchymal destruction in some patients (9).  
 
Normal and damaged airway mucosa 
In the airways and lungs, the epithelial lining of the mucosa forms the frontline line of defence 
against outside environmental exposure (11). It is a mechanical barrier to toxins emanating 
from smoke and infective microorganisms, through mucus secretion (12) and ciliary clearance 
(13). Further, epithelial cells also protect the underlying mucosa by producing several 
antibacterial, oxidising molecules, proteases and cellular tight junctions make them 
impregnable to toxin damage (14), as well as innate immune responses to protect against 
infection (1-3, 15-17). However, persistent exposure to external insults damages the normal 
architecture of the epithelium, pathologically indicated by squamous cell metaplasia of the 
normal pseudostratified columnar tissue, basal cell abnormalities and reprogramming, and 
goblet cell hyperplasia (18-20). The fundamental alterations that occur in epithelial cells is 
through inducible genomic and transcriptomic reprogramming (21, 22). This is directly linked 
to epithelial mesenchymal transition (EMT), a process of profound epithelial cell plasticity. 
Cells progressively lose their polarity and adhesiveness, and become migratory by gaining 
mesenchymal characteristics while progressively losing epithelial associated markers such as 
E-cadherin (19, 23-25).  
 
EMT in COPD 
In COPD, there is emerging evidence of EMT being associated with airway remodelling and 
obliteration, which have been shown in idiopathic pulmonary fibrosis (IPF) and cancer (26-
28). EMT is now increasingly considered as a possible core pathophysiological factor in COPD 
progression (29). This is especially evident from our initial observations of increased epithelial 
expression of mesenchymal markers such as S100A4 and vimentin in large and small airways 
of COPD patients compared to non-smokers (30, 31). Other consequences of EMT in COPD 
are increased cleft formation in the underlying reticular basement membrane (Rbm) (32, 33). 
This is suggestive of matrix metalloproteases (MMPs) activity, especially MMP9, whose 
epithelial and Rbm cell expression significantly increases in COPD patients (34-36). Further, 
in vitro evidence showed that cigarette smoke extract (CSE) exposure of normal primary 
human broncho-epithelial cells (pHBECs) induced EMT activity and increased expression of 
mesenchymal markers such as N-cadherin and α-smooth muscle actin (αSMA) with 
concomitant decreases in E-cadherin and α-catenin (37). This may occur via ROS production, 
increased TGF-β1 expression and decreased cAMP levels. Roles for urokinase plasminogen 
activation receptor (uPAR) in modulating EMT and direct associations between uPAR and 
vimentin expression in were also suggested (37). Mitochondrial dysfunction can also lead to 
EMT in smokers and COPD, hence cancer (38). 
 
PDE4 inhibitors abrogated EMT events by increasing cAMP levels (39, 40). Inhibiting TGF-
β1 with monoclonal antibodies, during in vitro differentiation of pHBECs prevented 
mesenchymal release of vimentin and fibronectin (41). Notably, our group reported elevated 
levels of epidermal growth factor receptor (EGFR) expression, a member of the ErbB (v-erb-b 
oncogene homolog) family of tyrosine kinase receptors, especially in areas that were positive 
for EMT markers (34). We also observed that EGFR was ubiquitous in both large and small 
airway epithelium of current and ex-smokers with COPD, and their expression was greater than 
smokers with normal lung function, indicating COPD is associated with exaggerated EGFR 
expression (30). EGFR levels in the small airways of COPD patients is associated with airway 
functionality.  
 
Potential EMT treatments 
In a “proof of concept” randomized controlled trial, we reported that inhaled corticosteroid 
fluticasone propionate is effective in reducing mesenchymal expression S100A4, vimentin, 
EGFR and MM9 expression in COPD patients (4, 28, 42-44). This is the first clinical study to 
show the anti-EMT effects of ICS. We also observed effects on vascular remodelling in COPD 
patients (45), angiogenesis (46) is also major part of EMT when associated with the formation 
of pro-cancer stroma (47). In epidemiological studies, it is observed that ICS treatment of 
COPD patients significantly reduces lung cancer risk but the underlying mechanisms are not 
clear (48). It is quite possible that ICS provide protection against lung cancer by ameliorating 
the EMT process in COPD patients (42, 43). However, ICS are reserved for more severe forms 
of COPD and predispose to pneumonia (49) by suppressing immunity (1-4, 50). Consequently, 
there is a critical need for new drugs, which can be given early in the disease to protect against 
lung cancer (4, 28, 44). It is important to note in this context that 70% of lung cancers occur in 
early disease. EMT certainly seems to be a novel therapeutic target in COPD and potentially 
lung cancer (42, 43).  
 
EGF:EGFR family as therapeutic target 
The role of EGFR in lung cancer is well documented and mutations in its tyrosine kinase 
domain are observed in 25% of non-small cell lung carcinoma (NSCLC) (51). Largely, these 
mutations are attributed to short in-frame deletions in exon 19 or as point mutations in exon 21 
(52). These aberrations lead to constitutive activation of the tyrosine kinases, causing 
unrestricted cellular growth and proliferation (52). Previous studies have attributed EGFR and 
its ligand EGF binding as major contributors to squamous cell metaplasia, the outgrowth of 
epithelial cells most notably in smokers and COPD, and signals for cancer initiation (53, 54). 
EGFR is also utilized by virus such as influenza A virus to cause infection, and infections are 
emerging as promoting lung cancer (55), again EMT could be central to this (2, 56). 
Interestingly, in smokers and COPD patients, both EGFR and mesenchymal markers such as 
S100A4 and vimentin are highly expressed, but more so in basal epithelial cells compared to 
the more differentiated ciliated epithelium (30, 57). This potentially makes basal cells a viable 
“stem” cell-like population capable of cellular transition and increasing their vulnerability to a 
cancer phenotype. 
 
Although EGF is considered as the main ligand that induce EGFR activity, other ligands of the 
EGF superfamily such as transforming growth factor-α (TGF-α), heparin-binding EGF-like 
growth factor (HB-EGF), amphiregulin (AREG), betacellulin (BTC), epiregulin (EREG), and 
epigen (EPGN) also play crucial roles in EGFR stimulation and regulation (58). Among these 
ligands for EGFR, the role of HB-EGF has been particularly found to be important and its 
negation results in multiple mammalian embryonic development abnormalities including 
postnatal lethal consequences such as malformed heart valves, hypertrophic cardiomyocytes, 
and hypoplastic lungs (59). HB‐EGF is also highly expressed in various forms of cancers, 
including lung, wherein it is transformed from a benign proHB-EGF to an active HB-EGF 
motif essentially through ectodomain shedding actions carried out by a disintegrin and 
metalloproteinase (ADAM) group of proteases (58). Once cleaved, HB-EGF causes rapid 
phosphorylation of EGFR that activates intracellular mitogen activated protein kinase (MAPK) 
signalling pathways, subsequently increasing cellular propensity to proliferate and invade (52, 
59). Interestingly, the ectodomain shedding of proHB-EGF also induces the transactivation of 
both extra- and intra-cellular receptors, thus widening the scope of their cellular signalling 
repertoire, which again could be linked to EMT progression, as shown in figure 1 (60-63). In 
epidermal cells such as keratinocytes HB-EGF under physiological conditions plays an 
important role in re-epithelization in response to injury and is active in skin wound healing by 
inducing increases in keratinocyte proliferation (64). In smokers and COPD patients, oxidative 
stress caused by toxins from cigarette smoke is a crucial factor causing lung epithelial injury, 
and these alterations in pathological conditions could generate large numbers of EGFR ligand 
including HB-EGFR.  
 
Role of HB-EGFR in promoting EMT 
The recent study by Lai et al., (65) demonstrated increases in HB-EGF levels in the sputum 
and lung tissue of smokers and COPD patients compared to non-smoking controls. Moreover, 
increases in sputum levels and lung tissue expression of HB-EGF were prominent in smokers 
with or without COPD rather than ex-smokers. This suggest that smoking alone may induce 
increase in HB-EGF concentrations, while smoking cessation could  abrogate this effect, which 
warrants further study. Again, of significant patho-physiological consequence was the 
association of increased HB-EGF sputum levels with increasing severity of the disease (GOLD 
stage I to IV), further indicating that the potent activation of these pathways may occur in later 
stages of the disease. However, this needs to be deciphered mechanistically. The authors further 
examined the role of HB-EGF in changes in airway cellular function and found that it induced 
EMT in human bronchial epithelial (HBE) cells, which was confirmed by increases in 
mesenchymal marker expression such as N-cadherin and vimentin and reductions in the 
epithelial marker E-cadherin. Interestingly, associations were also found between increased 
levels of sputum HB-EGF and mesenchymal marker expression in the lung tissue. Similarly in 
previous studies, HB-EGF-overexpressing keratinocytes displayed a characteristic EMT 
phenotype which included reduced E-cadherin expression, increased vimentin and cellular 
redistribution of nuclear proteins β-catenin, SNAIL and ZEB-1 (64). Further evidence is 
provided by breast cancer research wherein cells with aberrant expression of EGFR expression 
undergo EMT related changes via stimulation of the ligands HB-EGF and cytokines such as 
TNFα (63). Increases occur in perinuclear TWIST (an EMT associated transcription factor) 
expression via activation of the STAT3 pathway (figure 1).  
 
There is emerging evidence that EMT in COPD and other chronic lung diseases is activated by 
canonical pathways such as TGF-β, which induce expression of nuclear transcription factors 
pSMAD2/3 and reduced inhibitory SMAD6/7 expression (66, 67). Interestingly, TGF-β and 
EGFR pathway transactivation are observed in cancer cells and their synergism induces EMT 
related phenotypic changes (63). TGF-β also induces and promotes the increased expression of 
ligand EGF, EGFR and its associated signalling pathways (68). Although, TGFβ triggered 
pathways are crucial, other canonical pathways such as Wingless/integrase-1 (Wnt) mediate 
epithelial changes in COPD pathology (69). Nicotine, a major component of cigarette smoke 
was found to promote EMT related phenotypic changes in bronchial epithelial cells via WNT-
3A/β-catenin-dependent events (70). Adding to complexity is the more recent evidence of 
active non-canonical pathways of Wnt signalling in bronchial epithelial cells from smokers and 
COPD patients. Wnt5B modulated EMT changes independent of β-catenin possibly through 
the induction of TGF-β/SMAD3 signalling (71).  
 
Other reports have also suggested cross talk between TGF-β/SMADs and Wnt/β-catenin 
pathways in TGF-β induced alveolar epithelial cells and these interactions led to increases in 
αSMA positive myofibroblasts, the final outcome of  EMT (72). Our group previously reported 
increased expression of β-catenin in the large airways of both smokers and COPD patients (73). 
In the latter there were considerable increases in nuclear to cytoplasmic ratio of β-catenin 
suggesting active translocation and possible transcription of genes that are associated with 
transitional mesenchymal proteins. Further, transcriptional factors such as SNAIL1/2, ZEB1/2 
and TWIST, could also be independently activated by either canonical or non-canonical 
pathways, which again were found to translocate into the epithelial nucleus of COPD patients 
(73). Understanding the complex intricacies of HB-EGF/EGFR transactivation in regulating 
downstream EMT pathways may be an important way forward, and thus, further investigations 
of their roles in chronic lung disease manifestations are warranted.  
 
 
Role of the extracellular matrix (ECM) 
The main source of airflow limitation observed in COPD is the pathological changes that affect 
the airway wall, especially in the small airways, wherein noticeable tissue remodelling and 
scarring occurs, so that there is fundamental reorganization of the extracellular matrix (ECM) 
(10). These aberrant changes in the ECM have profound effects on the airway wall; the most 
critical is the gradual obliteration of the small airway lumen. The cell type that is primarily 
involved in ECM production and deposition are the active fibroblasts called myofibroblasts. 
These cells are of mesenchymal origin, have a spindle-shaped morphology, and are contractile 
(74). The contractible nature of myofibroblasts is associated with the expression of αSMA 
myofilaments, which form part of the non-muscle cell population. Interestingly, there have 
been contrasting data on myofibroblast populations in human bronchi and bronchiolar tissue. 
Lofdahl et al., (75) showed increases in αSMA positive cells in the lamina propria of the large 
airways in COPD patients compared to non-smoking controls, although changes in the 
expression levels were not so distinct in small airways (76). In contrast, fibroblasts isolated 
from the distal end of the small airways from COPD patients had increased contractile 
properties, associated with increases in myofibroblasts (77). Myofibroblast secretes a broad 
repertoire of ECM proteins that includes fibrous proteins such as collagen and elastin, and 
glycoproteins such as fibronectin, tenascin C, and some proteoglycans (78, 79). Further, co-
localization of αSMA positive fibroblastic cells along with collagen expression in the small 
airways in COPD provides essential evidence of their close association and interactions (80). 
Although, the presence of myofibroblasts has been confirmed, there has been little direct 
evidence of their origins, differentiation and regulation. Thus, the current observation of Lai et 
al., (65) of HB-EGF regulating fibroblastic changes may hold both clinical and therapeutic 
significance. Their finding of dose dependent increases in collagen I, III and αSMA expression 
in fibroblasts treated with HB-EGF, provides initial proof-of-concept that this ligand is also 
involved in fibroblast proliferation and maturation, which is further evident from increases in 
phosphorylated ERK and p38 (65). Nevertheless, further independent mechanistic studies are 
required to elucidate whether these are EGFR driven or are their other more complex 
interactions at play.  
 
Conclusions 
We consider that there is sufficient clinical evidence to suggest that EMT plays an important 
role in disease manifestations of COPD, and is thus a new therapeutic target. However, few 
studies have examined the molecular mechanisms that underlie this process. The study by Lai 
et al, provides crucial physiological and mechanistic understanding of the role of EGF ligand 
HB-EGF in regulating EMT and fibrosis, possibly through yet unexplored transactivation 
pathways. Other studies, including in vivo mouse models that replicate the pathologic features 
of EMT and fibrosis (81), and potentially exacerbations (82-90), could be valuable in 
elucidating mechanisms identifying therapeutic targets and test new therapies (91). Validation 
using combinations of in vivo and ex vivo human studies (45, 92-96) will provide powerful 
evidence for their roles and potential targeting in COPD (82, 97). There could be wider 
implications for other lung diseases such as idiopathic pulmonary fibrosis (IPF) and lung cancer 
where EMT activity and fibrosis are prevalent (26, 81, 98). Further, possible new therapeutic 
strategies can now be designed that mitigates these interactions, though further research in this 
area is mandated.  
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 Figure 1: The potential role of HB-EGF like growth factors in promoting epithelial-
mesenchymal transition (EMT). 
